FN1 and colorectal carcinoma: To determine whether EDB-FN overexpression can be used as a molecular marker to differentiate between non-resistant and drug-resistant CRC tumors, MRMI was performed using EDB-FN-targeting contrast agent MT218 51 in athymic nu/nu mice bearing subcutaneous xenografts of DLD-1, DLD1-DR, RKO, and RKO-DR.